UK markets closed

Regeneron Pharmaceuticals, Inc. (0R2M.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
908.38+0.88 (+0.10%)
At close: 07:04PM BST
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.14
52-week change 329.15%
S&P500 52-week change 323.06%
52-week high 3998.57
52-week low 3689.00
50-day moving average 3947.92
200-day moving average 3834.06

Share statistics

Avg vol (3-month) 31.96k
Avg vol (10-day) 3336
Shares outstanding 5108.03M
Implied shares outstanding 6N/A
Float 8102.75M
% held by insiders 12.58%
% held by institutions 189.29%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 30.14%
Operating margin (ttm)29.20%

Management effectiveness

Return on assets (ttm)8.49%
Return on equity (ttm)16.26%

Income statement

Revenue (ttm)13.12B
Revenue per share (ttm)122.93
Quarterly revenue growth (yoy)0.60%
Gross profit (ttm)N/A
EBITDA 4.65B
Net income avi to common (ttm)3.95B
Diluted EPS (ttm)70.31
Quarterly earnings growth (yoy)-3.10%

Balance sheet

Total cash (mrq)10.84B
Total cash per share (mrq)100.92
Total debt (mrq)2.79B
Total debt/equity (mrq)10.74%
Current ratio (mrq)5.69
Book value per share (mrq)242.47

Cash flow statement

Operating cash flow (ttm)4.59B
Levered free cash flow (ttm)2.76B